已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

医学 射血分数 赛马鲁肽 心力衰竭 心脏病学 内科学 糖尿病 内分泌学 2型糖尿病 利拉鲁肽
作者
Nils Krüger,Sebastian Schneeweiß,Kenshiro Fuse,Sofiya Matseyko,Sushama Kattinakere Sreedhara,Georg Hahn,Heribert Schunkert,Shirley V. Wang
出处
期刊:JAMA [American Medical Association]
卷期号:334 (14): 1255-1255 被引量:70
标识
DOI:10.1001/jama.2025.14092
摘要

Importance: Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes. Although early trials of semaglutide and tirzepatide have shown promising results in improving symptoms, those findings were based on few clinical events, leaving treatment recommendations uncertain. Objective: To evaluate the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic HFpEF in clinical practice. Design, Setting, and Participants: Five cohort studies using national US health care claims data from 2018 to 2024. Two cohort studies emulated the STEP-HFpEF DM (semaglutide) and SUMMIT (tirzepatide) trials to benchmark results. Eligibility criteria were then expanded to evaluate treatment effects in patients typically treated in clinical practice. Finally, a head-to-head comparison of tirzepatide and semaglutide was implemented. Follow-up was up to 52 weeks. Exposures: New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy. Main Outcomes and Measures: The primary end point was a composite of hospitalization for heart failure or all-cause mortality. Negative control outcomes, secondary end points, subgroups, and sensitivity analyses were prespecified. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by fitting proportional hazards models with propensity score weighting to adjust for a comprehensive set of pretreatment patient characteristics. Results: Benchmarking of the 2 trial emulations demonstrated high agreement on all prespecified metrics. In analyses using expanded eligibility criteria, 58 333 patients were included in the semaglutide vs sitagliptin cohort, 11 257 for tirzepatide vs sitagliptin, and 28 100 for tirzepatide vs semaglutide. Initiators of semaglutide (HR, 0.58 [95% CI, 0.51-0.65]) and tirzepatide (HR, 0.42 [95% CI, 0.31-0.57]) had substantially lower risk of the primary end point compared with sitagliptin. Tirzepatide had no meaningfully lowered risk compared with semaglutide (HR, 0.86 [95% CI, 0.70-1.06]). Negative controls, secondary end points, subgroups, and sensitivity analyses showed consistent results. No substantially increased risk was observed for select safety end points. Conclusions and Relevance: In patients with cardiometabolic HFpEF, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide. Trial Registration: ClinicalTrials.gov Identifiers: NCT06914102, NCT06914154, NCT06914141.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
乐乐的应助被3921337477采纳,获得10
1秒前
vc发布了新的文献求助10
2秒前
LifeOnMars完成签到,获得积分10
2秒前
学霸业的应助被科研小小怪采纳,获得10
3秒前
u611408发布了新的文献求助60
3秒前
燦燦完成签到 ,获得积分10
5秒前
刘宇童完成签到 ,获得积分10
6秒前
6秒前
爱撒娇的从寒完成签到,获得积分10
7秒前
7秒前
7秒前
脑洞疼的应助被DW采纳,获得10
7秒前
3921337477的应助被u575067采纳,获得60
9秒前
alex的应助被洋芋二号采纳,获得10
9秒前
xxx完成签到 ,获得积分10
10秒前
无花果的应助被qq采纳,获得10
10秒前
阳阳杜完成签到 ,获得积分10
11秒前
yyyyy发布了新的文献求助30
12秒前
创伤章鱼发布了新的文献求助10
12秒前
无奈板栗完成签到,获得积分20
14秒前
cbh完成签到,获得积分10
14秒前
15秒前
芦苇红柳完成签到 ,获得积分10
18秒前
漆漆完成签到 ,获得积分10
18秒前
19秒前
20秒前
科研通AI65的应助被DW采纳,获得10
21秒前
21秒前
无奈板栗发布了新的文献求助10
22秒前
yy完成签到,获得积分10
22秒前
qq发布了新的文献求助10
23秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
23秒前
学霸业的应助被科研通管家采纳,获得10
23秒前
Owen的应助被科研通管家采纳,获得10
24秒前
24秒前
情怀的应助被科研通管家采纳,获得10
24秒前
科研通AI65的应助被科研通管家采纳,获得10
24秒前
u575067发布了新的文献求助60
24秒前
Maestro_S的应助被科研通管家采纳,获得10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184867
求助须知:如何正确求助?哪些是违规求助? 9573803
关于积分的说明 21833148
捐赠科研通 7782177
什么是DOI,文献DOI怎么找? 3434414
关于科研通互助平台的介绍 2558563
邀请新用户注册赠送积分活动 2481067